Nanoarchitectures in Management of Fungal Diseases: An Overview

Vijay Mishra; Manvendra Singh; Yachana Mishra; Nitin Charbe; Pallavi Nayak; Kalvatala Sudhakar; Alaa A. A. Aljabali; Seyed H. Shahcheraghi; Hamid Bakshi; Ángel Serrano-aroca; Murtaza M. Tambuwala

doi:10.3390/app11157119

Nanoarchitectures in Management of Fungal Diseases: An Overview

Vijay Mishra
, Manvendra Singh
, Yachana Mishra
, Nitin Charbe
, Pallavi Nayak
, Kalvatala Sudhakar
, Alaa A. A. Aljabali
, Seyed H. Shahcheraghi
, Hamid Bakshi
, Ángel Serrano-aroca
, Murtaza M. Tambuwala

Research output: Contribution to journal › Review article › peer-review

27 Citations (Scopus)

207 Downloads (Pure)

Abstract

Fungal infections, from mild itching to fatal infections, lead to chronic diseases and death. Antifungal agents have incorporated chemical compounds and natural products/phytoconstituents in the management of fungal diseases. In contrast to antibacterial research, novel antifungal drugs have progressed more swiftly because of their mild existence and negligible resistance of infections to antifungal bioactivities. Nanotechnology-based carriers have gained much attention due to their magnificent abilities. Nanoarchitectures have served as excellent carriers/drug delivery systems (DDS) for delivering antifungal drugs with improved antifungal activities, bioavailability, targeted action, and reduced cytotoxicity. This review outlines the different fungal diseases and their treatment strategies involving various nanocarrier-based techniques such as liposomes, transfersomes, ethosomes, transethosomes, niosomes, spanlastics, dendrimers, polymeric nanoparticles, polymer nanocomposites, metallic nanoparticles, carbon nanomaterials, and nanoemulsions, among other nanotechnological approaches.

Original language	English
Article number	e7119
Pages (from-to)	1-19
Number of pages	19
Journal	Applied Sciences
Volume	11
Issue number	15
Early online date	31 Jul 2021
DOIs	https://doi.org/10.3390/app11157119
Publication status	Published online - 31 Jul 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

antifungal drugs
drug delivery
fungal infection
nanoarchitecture carriers
Nanoarchitecture carriers
Drug delivery
Fungal infection
Antifungal drugs

Access to Document

10.3390/app11157119Licence: CC BY

Final published versionFinal published version, 1.79 MBLicence: CC BY

Cite this

@article{e487df36ed7a44e09ea727dcd249f823,

title = "Nanoarchitectures in Management of Fungal Diseases: An Overview",

abstract = "Fungal infections, from mild itching to fatal infections, lead to chronic diseases and death. Antifungal agents have incorporated chemical compounds and natural products/phytoconstituents in the management of fungal diseases. In contrast to antibacterial research, novel antifungal drugs have progressed more swiftly because of their mild existence and negligible resistance of infections to antifungal bioactivities. Nanotechnology-based carriers have gained much attention due to their magnificent abilities. Nanoarchitectures have served as excellent carriers/drug delivery systems (DDS) for delivering antifungal drugs with improved antifungal activities, bioavailability, targeted action, and reduced cytotoxicity. This review outlines the different fungal diseases and their treatment strategies involving various nanocarrier-based techniques such as liposomes, transfersomes, ethosomes, transethosomes, niosomes, spanlastics, dendrimers, polymeric nanoparticles, polymer nanocomposites, metallic nanoparticles, carbon nanomaterials, and nanoemulsions, among other nanotechnological approaches.",

keywords = "antifungal drugs, drug delivery, fungal infection, nanoarchitecture carriers, Nanoarchitecture carriers, Drug delivery, Fungal infection, Antifungal drugs",

author = "Vijay Mishra and Manvendra Singh and Yachana Mishra and Nitin Charbe and Pallavi Nayak and Kalvatala Sudhakar and Aljabali, \{Alaa A. A.\} and Shahcheraghi, \{Seyed H.\} and Hamid Bakshi and {\'A}ngel Serrano-aroca and Tambuwala, \{Murtaza M.\}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = jul,

day = "31",

doi = "10.3390/app11157119",

language = "English",

volume = "11",

pages = "1--19",

journal = "Applied Sciences",

issn = "2076-3417",

publisher = "Multidisciplinary Digital Publishing Institute",

number = "15",

}

TY - JOUR

T1 - Nanoarchitectures in Management of Fungal Diseases: An Overview

AU - Mishra, Vijay

AU - Singh, Manvendra

AU - Mishra, Yachana

AU - Charbe, Nitin

AU - Nayak, Pallavi

AU - Sudhakar, Kalvatala

AU - Aljabali, Alaa A. A.

AU - Shahcheraghi, Seyed H.

AU - Bakshi, Hamid

AU - Serrano-aroca, Ángel

AU - Tambuwala, Murtaza M.

PY - 2021/7/31

Y1 - 2021/7/31

N2 - Fungal infections, from mild itching to fatal infections, lead to chronic diseases and death. Antifungal agents have incorporated chemical compounds and natural products/phytoconstituents in the management of fungal diseases. In contrast to antibacterial research, novel antifungal drugs have progressed more swiftly because of their mild existence and negligible resistance of infections to antifungal bioactivities. Nanotechnology-based carriers have gained much attention due to their magnificent abilities. Nanoarchitectures have served as excellent carriers/drug delivery systems (DDS) for delivering antifungal drugs with improved antifungal activities, bioavailability, targeted action, and reduced cytotoxicity. This review outlines the different fungal diseases and their treatment strategies involving various nanocarrier-based techniques such as liposomes, transfersomes, ethosomes, transethosomes, niosomes, spanlastics, dendrimers, polymeric nanoparticles, polymer nanocomposites, metallic nanoparticles, carbon nanomaterials, and nanoemulsions, among other nanotechnological approaches.

AB - Fungal infections, from mild itching to fatal infections, lead to chronic diseases and death. Antifungal agents have incorporated chemical compounds and natural products/phytoconstituents in the management of fungal diseases. In contrast to antibacterial research, novel antifungal drugs have progressed more swiftly because of their mild existence and negligible resistance of infections to antifungal bioactivities. Nanotechnology-based carriers have gained much attention due to their magnificent abilities. Nanoarchitectures have served as excellent carriers/drug delivery systems (DDS) for delivering antifungal drugs with improved antifungal activities, bioavailability, targeted action, and reduced cytotoxicity. This review outlines the different fungal diseases and their treatment strategies involving various nanocarrier-based techniques such as liposomes, transfersomes, ethosomes, transethosomes, niosomes, spanlastics, dendrimers, polymeric nanoparticles, polymer nanocomposites, metallic nanoparticles, carbon nanomaterials, and nanoemulsions, among other nanotechnological approaches.

KW - antifungal drugs

KW - drug delivery

KW - fungal infection

KW - nanoarchitecture carriers

KW - Nanoarchitecture carriers

KW - Drug delivery

KW - Fungal infection

KW - Antifungal drugs

UR - https://www.mdpi.com/2076-3417/11/15/7119

UR - https://www.scopus.com/pages/publications/85112001756

U2 - 10.3390/app11157119

DO - 10.3390/app11157119

M3 - Review article

SN - 2076-3417

VL - 11

SP - 1

EP - 19

JO - Applied Sciences

JF - Applied Sciences

IS - 15

M1 - e7119

ER -

Nanoarchitectures in Management of Fungal Diseases: An Overview

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Molecular analysis of the effects of crocin on acute myeloid leukaemia, pancreatic and colon cancer

Cite this

Nanoarchitectures in Management of Fungal Diseases: An Overview

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Student theses

Molecular analysis of the effects of crocin on acute myeloid leukaemia, pancreatic and colon cancer

Cite this